BriaCell Therapeutics (FRA:8BT) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8BT BriaCell Therapeutics Corp FRA:8BT
38 GF Score
Price €3.48
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics  (FRA:8BT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BriaCell Therapeutics Cyclically Adjusted PB Ratio Related Terms


BriaCell Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics Cyclically Adjusted PB Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.36 2.73 0.77 0.13

BriaCell Therapeutics Quarterly Data
Jan21 Apr21 Oct21 Jan22 Apr22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.13 0.18 0.06 0.06

FRA:8BT vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:8BT
38GF Score
BriaCell Therapeutics Corp FRA:8BT
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2026 is calculated as:

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Apr. 2026 was:

Adj_Book=Book Value per Share/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=2.752/132.7364*132.7364
=2.752

Current CPI (Apr. 2026) = 132.7364.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201601 254.521 100.184 337.220
201604 489.894 101.370 641.483
201607 347.488 101.844 452.894
201610 663.048 102.002 862.836
201701 569.209 102.318 738.434
201704 614.336 103.029 791.476
201707 269.475 103.029 347.176
201710 337.504 103.424 433.160
201801 151.729 104.056 193.550
201804 555.317 105.320 699.874
201807 228.898 106.110 286.336
201810 88.970 105.952 111.461
201901 -144.965 105.557 -182.291
201904 131.614 107.453 162.582
201907 -132.615 108.243 -162.623
201910 -1.015 107.927 -1.248
202001 -423.690 108.085 -520.321
202004 -522.266 107.216 -646.579
202007 -579.720 108.401 -709.861
202010 -561.581 108.638 -686.150
202101 -566.584 109.192 -688.756
202104 228.013 110.851 273.031
202110 467.129 113.695 545.363
202201 400.254 114.801 462.785
202204 419.798 118.357 470.802
202210 101.071 121.517 110.403
202301 -11.398 121.596 -12.442
202304 -51.590 123.571 -55.416
202307 -32.154 124.914 -34.167
202310 22.344 125.310 23.668
202401 -71.867 125.072 -76.271
202404 -54.712 126.890 -57.233
202407 -20.355 128.075 -21.096
202410 14.178 127.838 14.721
202501 10.533 127.443 10.971
202504 16.018 129.102 16.469
202507 8.039 130.290 8.190
202510 4.300 130.603 4.370
202601 3.503 130.366 3.567
202604 2.752 132.736 2.752

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics Business Description

Other Exchanges BCTX:USABCT:Canada
Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
38GF Score

Get the complete analysis for FRA:8BT

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.48
Price